Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 155

1.

Monitoring cholesterol levels: measurement error or true change?

Glasziou PP, Irwig L, Heritier S, Simes RJ, Tonkin A; LIPID Study Investigators.

Ann Intern Med. 2008 May 6;148(9):656-61.

PMID:
18458278
[PubMed - indexed for MEDLINE]
2.

Long-term assessment of psychological well-being in a randomized placebo-controlled trial of cholesterol reduction with pravastatin. The LIPID Study Investigators.

Stewart RA, Sharples KJ, North FM, Menkes DB, Baker J, Simes J.

Arch Intern Med. 2000 Nov 13;160(20):3144-52.

PMID:
11074745
[PubMed - indexed for MEDLINE]
3.
4.

Cholesterol-lowering therapy with pravastatin in patients with average cholesterol levels and established ischaemic heart disease: is it cost-effective?

Glasziou PP, Eckermann SD, Mulray SE, Simes RJ, Martin AJ, Kirby AC, Hall JP, Caleo S, White HD, Tonkin AM.

Med J Aust. 2002 Oct 21;177(8):428-34.

PMID:
12381252
[PubMed - indexed for MEDLINE]
5.

Monitoring adherence to drug treatment by using change in cholesterol concentration: secondary analysis of trial data.

Bell KJ, Kirby A, Hayen A, Irwig L, Glasziou P.

BMJ. 2011 Jan 21;342:d12. doi: 10.1136/bmj.d12.

PMID:
21257657
[PubMed - indexed for MEDLINE]
Free Article
8.

[Clinical study of the month. The LIPID study: "long-term intervention with pravastatin in ischaemic disease"].

Scheen AJ.

Rev Med Liege. 1999 Jan;54(1):2-3. French.

PMID:
10081301
[PubMed - indexed for MEDLINE]
9.

Risk factors for non-haemorrhagic stroke in patients with coronary heart disease and the effect of lipid-modifying therapy with pravastatin.

West MJ, White HD, Simes RJ, Kirby A, Watson JD, Anderson NE, Hankey GJ, Wonders S, Hunt D, Tonkin AM.

J Hypertens. 2002 Dec;20(12):2513-7.

PMID:
12473877
[PubMed - indexed for MEDLINE]
10.

Cost-effectiveness of cholesterol-lowering therapy with pravastatin in patients with previous acute coronary syndromes aged 65 to 74 years compared with younger patients: results from the LIPID study.

Tonkin AM, Eckermann S, White H, Friedlander D, Glasziou P, Magnus P, Kirby A, Mulray S, Denton M, Sallaberger M, Hunt D, Simes J; LIPID Study Group.

Am Heart J. 2006 Jun;151(6):1305-12.

PMID:
16781242
[PubMed - indexed for MEDLINE]
11.

Randomized, controlled trial of secondary prevention of coronary sclerosis in normocholesterolemic patients using pravastatin: final 5-year angiographic follow-up of the Prevention of Coronary Sclerosis (PCS) study.

Nakagawa T, Kobayashi T, Awata N, Sato S, Reiber JH, Nakajima H, Toyama YN, Hiraoka H, Kato O, Kirino M, Kobayashi T, Takeda Y, Yachiku K, Iida M, Itoh T, Shibata N.

Int J Cardiol. 2004 Oct;97(1):107-14.

PMID:
15336816
[PubMed - indexed for MEDLINE]
12.

Prognostic utility of apoB/AI, total cholesterol/HDL, non-HDL cholesterol, or hs-CRP as predictors of clinical risk in patients receiving statin therapy after acute coronary syndromes: results from PROVE IT-TIMI 22.

Ray KK, Cannon CP, Cairns R, Morrow DA, Ridker PM, Braunwald E.

Arterioscler Thromb Vasc Biol. 2009 Mar;29(3):424-30. doi: 10.1161/ATVBAHA.108.181735. Epub 2009 Jan 2.

PMID:
19122170
[PubMed - indexed for MEDLINE]
Free Article
13.

Comparative effects of 10-mg versus 80-mg Atorvastatin on high-sensitivity C-reactive protein in patients with stable coronary artery disease: results of the CAP (Comparative Atorvastatin Pleiotropic effects) study.

Bonnet J, McPherson R, Tedgui A, Simoneau D, Nozza A, Martineau P, Davignon J; CAP Investigators.

Clin Ther. 2008 Dec;30(12):2298-313. doi: 10.1016/j.clinthera.2008.12.023.

PMID:
19167589
[PubMed - indexed for MEDLINE]
14.

Relationship of oxidized phospholipids and biomarkers of oxidized low-density lipoprotein with cardiovascular risk factors, inflammatory biomarkers, and effect of statin therapy in patients with acute coronary syndromes: Results from the MIRACL (Myocardial Ischemia Reduction With Aggressive Cholesterol Lowering) trial.

Fraley AE, Schwartz GG, Olsson AG, Kinlay S, Szarek M, Rifai N, Libby P, Ganz P, Witztum JL, Tsimikas S; MIRACL Study Investigators.

J Am Coll Cardiol. 2009 Jun 9;53(23):2186-96. doi: 10.1016/j.jacc.2009.02.041.

PMID:
19497447
[PubMed - indexed for MEDLINE]
Free Article
15.

Pravastatin for cardiovascular event primary prevention in patients with mild-to-moderate hypertension in the Management of Elevated Cholesterol in the Primary Prevention Group of Adult Japanese (MEGA) Study.

Kushiro T, Mizuno K, Nakaya N, Ohashi Y, Tajima N, Teramoto T, Uchiyama S, Nakamura H; Management of Elevated Cholesterol in the Primary Prevention Group of Adult Japanese Study Group.

Hypertension. 2009 Feb;53(2):135-41. doi: 10.1161/HYPERTENSIONAHA.108.120584. Epub 2008 Dec 22.

PMID:
19104004
[PubMed - indexed for MEDLINE]
Free Article
16.

Primary prevention of cardiovascular disease with pravastatin in Japan (MEGA Study): a prospective randomised controlled trial.

Nakamura H, Arakawa K, Itakura H, Kitabatake A, Goto Y, Toyota T, Nakaya N, Nishimoto S, Muranaka M, Yamamoto A, Mizuno K, Ohashi Y; MEGA Study Group.

Lancet. 2006 Sep 30;368(9542):1155-63.

PMID:
17011942
[PubMed - indexed for MEDLINE]
17.

Seasonal variation in lipids in patients following acute coronary syndrome on fixed doses of Pravastatin (40 mg) or Atorvastatin (80 mg) (from the Pravastatin or Atorvastatin Evaluation and Infection Therapy-Thrombolysis In Myocardial Infarction 22 [PROVE IT-TIMI 22] Study).

Tung P, Wiviott SD, Cannon CP, Murphy SA, McCabe CH, Gibson CM.

Am J Cardiol. 2009 Apr 15;103(8):1056-60. doi: 10.1016/j.amjcard.2008.12.034. Epub 2009 Feb 21.

PMID:
19361589
[PubMed - indexed for MEDLINE]
18.

Differences in cardiovascular mortality between Australia and New Zealand according to socioeconomic status: findings from the Long-Term Intervention with Pravastatin in Ischaemic Disease (LIPID) Study.

Stewart RA, North FM, Sharples KJ, Simes RJ, Tonkin AM, White HD; Long-term Intervention with Pravastatin in Ischaemic Disease Study Investigators.

N Z Med J. 2008 Feb 15;121(1269):11-23.

PMID:
18278078
[PubMed - indexed for MEDLINE]
19.

Randomized placebo-controlled trial assessing a treatment strategy consisting of pravastatin, vitamin E, and homocysteine lowering on plasma asymmetric dimethylarginine concentration in mild to moderate CKD.

Nanayakkara PW, Kiefte-de Jong JC, ter Wee PM, Stehouwer CD, van Ittersum FJ, Olthof MR, Teerlink T, Twisk JW, van Guldener C, Smulders YM.

Am J Kidney Dis. 2009 Jan;53(1):41-50. doi: 10.1053/j.ajkd.2008.06.016. Epub 2008 Sep 11.

PMID:
18786751
[PubMed - indexed for MEDLINE]
20.

Tolerability and effects on lipids of ezetimibe coadministered with pravastatin or simvastatin for twelve months: results from two open-label extension studies in hypercholesterolemic patients.

Strony J, Hoffman R, Hanson M, Veltri E.

Clin Ther. 2008 Dec;30(12):2280-97. doi: 10.1016/j.clinthera.2008.12.008.

PMID:
19167588
[PubMed - indexed for MEDLINE]
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk